AbbVie (NYSE: ABBV) reported Q1 EPS of $2.46, in-line with the analyst estimate of $2.46. Revenue for the quarter came in at $12.23 billion versus the consensus estimate of $12.18 billion.

GUIDANCE:

AbbVie sees FY2023 EPS of $10.72-$11.12, versus the consensus of $10.94.

For earnings history and earnings-related data on AbbVie (ABBV) click here.